{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:39:18Z","timestamp":1793475558887,"version":"4.5.0"},"reference-count":17,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2024,5,1]]},"abstract":"<jats:sec id=\"ab-ooi240012-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>In clinical trials, preoperative immune checkpoint inhibitors (ICIs) have shown clinical activity in advanced cutaneous squamous cell carcinoma (cSCC). However, these studies excluded patients with relevant comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi240012-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate radiologic and pathologic response rates to neoadjuvant-intent programed cell death protein 1 (PD-1) ICIs in a clinical population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi240012-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This cohort study of patients who were treated with neoadjuvant cemiplimab or pembrolizumab for advanced cSCC from January 2018 to January 2023 was conducted at 2 academic institutions in Boston, Massachusetts. Median follow-up was 9.5 months (range, 1.2-40.5).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi240012-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Cemiplimab or pembrolizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi240012-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Primary outcomes were radiologic and pathologic response rates. Secondary outcomes were 1-year recurrence-free survival, progression-free survival, disease-specific survival, and overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi240012-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>This cohort study included 27 patients (including 9 patients [33.3%] with a history of lymphoma). Most patients were male (18 of 27 [66.7%]), with a median age of 72 years (range, 53-87 years). Most primary tumors were located on the head\/neck (21 of 27 [77.8%]). There were no unexpected delays in surgery. The median number of doses before surgery was 3.5 (range, 1.0-10.0). Five patients (18.5%) ultimately declined to undergo planned surgery due to clinical responses or stability, and 1 (3.7%) did not undergo surgery due to progressive disease. The overall pathologic response rate (pathological complete response [pCR] or major pathological response) was 47.4% (9 of 19), and the overall radiologic response rate (radiologic complete response or partial response) was 50.0% (8 of 16). The pCR rate (7 of 19 [36.8%]) was higher than the radiologic complete response rate (2 of 16 [12.5%]). The pCR rate among patients with cSCC and concomitant lymphoma was 25.0%. The 1-year recurrence-free survival rate was 90.9% (95% CI, 50.8%-98.7%), progression-free survival was 83.3% (95% CI, 27.3%-97.5%), disease-specific survival was 91.7% (95% CI, 53.9%-98.8%), and overall survival was 84.6% (95% CI, 51.2%-95.9%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-ooi240012-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The results of this cohort study support the reproducibility of neoadjuvant-intent immunotherapy for cSCC in the clinical setting, including for patients with a history of lymphoma. Outside of clinical trials, it is not infrequent for patients to opt out of surgery for regressing tumors. The inclusion of higher-risk patients and preference for nonsurgical treatment are 2 factors that might explain the numerically lower pathologic response rate in this institutional experience.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaoto.2024.0259","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T11:06:54Z","timestamp":1711624014000},"page":"414","source":"Crossref","is-referenced-by-count":35,"title":["Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma"],"prefix":"10.1001","volume":"150","author":[{"given":"Emily Y.","family":"Kim","sequence":"first","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily S.","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia S.","family":"DeSimone","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia Z.","family":"Shalhout","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Massachusetts Eye and Ear, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn J.","family":"Hanna","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Miller","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysalyne","family":"Schmults","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni M.","family":"Rettig","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth K.","family":"Foreman","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts"},{"name":"Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosh","family":"Sethi","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manisha","family":"Thakuria","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann W.","family":"Silk","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"ooi240012r1","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012.","volume":"151","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"6","key":"ooi240012r2","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.jaad.2012.11.037","article-title":"Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012.","volume":"68","author":"Karia","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"16","key":"ooi240012r3","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1158\/1078-0432.CCR-21-0585","article-title":"Pilot phase II trial of neoadjuvant immunotherapy in locoregionally advanced, resectable cutaneous squamous cell carcinoma of the head and neck.","volume":"27","author":"Ferrarotto","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1-3","key":"ooi240012r4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/S1011-1344(01)00198-1","article-title":"The epidemiology of UV induced skin cancer.","volume":"63","author":"Armstrong","year":"2001","journal-title":"J Photochem Photobiol B"},{"issue":"13","key":"ooi240012r5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1056\/NEJM200103293441306","article-title":"Cutaneous squamous-cell carcinoma.","volume":"344","author":"Alam","year":"2001","journal-title":"N Engl J Med"},{"issue":"4","key":"ooi240012r6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1001\/jamadermatol.2022.0001","article-title":"Implications of satellitosis or in-transit metastasis in cutaneous squamous cell carcinoma: a prognostic omission in cancer staging systems.","volume":"158","author":"Smile","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"17","key":"ooi240012r9","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma.","volume":"387","author":"Gross","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"ooi240012r10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000897","article-title":"Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.","volume":"8","author":"Leiter","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"2","key":"ooi240012r11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"3","key":"ooi240012r12","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1158\/1078-0432.CCR-19-2379","article-title":"Pan-tumor pathologic scoring of response to PD-(L)1 blockade.","volume":"26","author":"Stein","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"ooi240012r14","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC).","volume":"27","author":"Menzies","year":"2021","journal-title":"Nat Med"},{"key":"ooi240012r15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.9507","article-title":"Towards organ preservation and cure via 2 infusions of immunotherapy only, in patients normally undergoing extensive and mutilating curative surgery for cutaneous squamous cell carcinoma: an investigator-initiated randomized phase II trial\u2014The MATISSE trial.","author":"Breukers","journal-title":"J Clin Oncol"},{"issue":"9","key":"ooi240012r16","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1001\/jamaoto.2023.1729","article-title":"Outcomes of treatment with neoadjuvant cemiplimab for patients with advanced, resectable cutaneous squamous cell carcinoma of the head and neck: secondary analysis of a phase 2 clinical trial.","volume":"149","author":"Ferrarotto","year":"2023","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"11","key":"ooi240012r17","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S1470-2045(23)00459-X","article-title":"Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.","volume":"24","author":"Gross","year":"2023","journal-title":"Lancet Oncol"},{"key":"ooi240012r7","unstructured":"US Food and Drug Administration. FDA approves cemiplimab-rwlc for metastatic or locally advanced cutaneous squamous cell carcinoma. Accessed February 23, 2023. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-cemiplimab-rwlc-metastatic-or-locally-advanced-cutaneous-squamous-cell-carcinoma"},{"key":"ooi240012r8","unstructured":"US Food and Drug Administration. FDA approves pembrolizumab for cutaneous squamous cell carcinoma. FDA. Accessed September 23, 2022. https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-pembrolizumab-cutaneous-squamous-cell-carcinoma"},{"key":"ooi240012r13","unstructured":"Amin? MB, Edge? S, Greene? F, , eds. AJCC cancer staging manual (8th edition). Accessed July 14, 2023. https:\/\/link.springer.com\/book\/9783319406176"}],"container-title":["JAMA Otolaryngology\u2013Head &amp; Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2816489\/jamaotolaryngology_kim_2024_oi_240012_1714577520.87327.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T11:01:23Z","timestamp":1715252483000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2816489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,1]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2024.0259","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,1]]}}}